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Abstract
Background: The systematic evaluation of the clinical con-
cordance of various 25-hydroxyvitamin D (25OHD) testing 
methods is presented. The need for this approach is raised 
by the discrepancies in the analytical performance of the 
available assays.
Methods: The analytical and clinical performance of six 
automated 25OHD assays and an in-house liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) method 
was investigated. Leftover serum samples (n = 162, SA: 
n = 114) were analyzed and all 21 assay combinations were 
evaluated. The utility of Cohen’s κ values was assessed 
by transforming them into minimum percentage agree-
ment (MPA). McNemar’s hypothesis test was employed for 
testing the symmetry of the disagreeing classification out-
comes within each method pair.
Results: Depending on the assay method, the ratio of results 
classified as positive ( < 20 ng/mL) was 13.5%–40.0%. The 
percentage agreement (PA) was 74.1%–92.6%. Compared 
to other methods, significantly more hypovitaminosis 
cases were delivered by DiaSorin Liaison® 25 OH vitamin D 
Total (DL) and significantly fewer by IDS-iSYS 25-Hydroxy 
Vitamin DS (II). The strongest clinical concordance was 
exerted by II vs. LC-MS/MS. The κ-derived MPA showed 
close similarity to the PA scores. McNemar’s tests con-
firmed the asymmetry of the disagreement in the classifi-
cation in 14 method combinations.
Conclusions: The presented approach allows the predic-
tion of the clinical consequences of a 25OHD method 
transfer. Differences in the clinical classification of assay 
results are likely encountered when transferring to a new 
method, even between assays standardized according to 
the Vitamin D Standardization Program (VDSP) Reference 
Method Procedure (RMP).
Keywords: 25-hydroxyvitamin D; hypovitaminosis D; 
immunoassay; liquid chromatography-tandem mass spec-
trometry; method comparison; multicriteria evaluation.
Introduction
There continues to be a considerable interest in the clinical 
assessment of vitamin D status, maintaining the increase 
in the number of the available automated and liquid 
chromatographic 25-hydroxyvitamin D (25OHD) testing 
methods [1–4]. Despite their preferred use, serious doubt 
has been cast on the comparability of the performance of 
the automated assays, which is a major issue because the 
threshold of hypovitaminosis D requiring intervention, 
most commonly 20 ng/mL (50 nmol/L), is not linked to 
any of the methods [5–7]. In addition, no consensus on 
the critical 25OHD levels in special patient groups such 
as children, the pregnant, the obese, the critically ill, or 
those undergoing hemodialysis is available, but once it 
is established, further thresholds are likely to be defined, 
increasing the complexity of method comparisons and 
potentially exacerbating the confusion over the interpre-
tation of test results [8–11].
Numerous studies have been published recently with 
the aim to compare the outputs of 25OHD assays. All of 
these works have compared the analytical performance to 
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that of a reference method [primarily liquid chromatog-
raphy coupled with tandem mass spectrometry (LC-MS/
MS) or ultraviolet detection, or radioimmunoassay], with 
the evaluation relying on linear regression (ordinary 
least squares, Passing-Bablok or Deming) combined with 
Bland-Altman analysis. Because of the complexity of the 
inconsistencies in the performance of the available assays 
and, possibly, the narrow range of the evaluation tools 
employed, this approach has not proven adequate for pre-
dicting the clinical consequences of transferring between 
25OHD testing methods [8, 12].
As a major step forward, the Vitamin D Standardiza-
tion Program (VDSP), an international effort to provide 
a framework for the standardization and harmonization 
of 25OHD assays, is underway. With a reference method 
procedure (RMP) allowing the 25OHD contents of blood 
samples to be traced back to standard reference materi-
als acknowledged by the National Institute of Standardi-
zation and Technology, USA, the VDSP is a very efficient 
platform for the credible evaluation the analytical perfor-
mance [13, 14]. Automated tests with their performance 
standardized in VDSP RMP have already been launched, 
including three assays discussed herein. The Vitamin D 
External Quality Assessment Scheme (DEQAS) has also 
contributed valuably to the identification of phenomena 
which have an impact on method performance [15–18].
The direct assessment of the clinical concordance of 
the results obtained with various 25OHD assays is equally 
important for comparing method performance, yet it has 
received much less attention. Such evaluation has occa-
sionally been included in a few studies by displaying 
patterns of the clinical classifications [19, 20], determin-
ing sensitivity and specificity [4, 20], assessing relative 
false positives and false negatives [21], or by calculating 
the percentage agreement (PA) of clinical classifications 
[16,  22] and/or Cohen’s κ values [4, 12, 23–25]. In each 
case, the evaluation was accomplished against the results 
obtained using the reference method, except for the work 
of Cavalier et al. who calculated the clinical concordance 
for all combinations of the compared assays [22].
In the present work, the pairwise combinations of 
seven 25OHD testing methods, six automated assays 
[Abbott Architect 25-OH Total Vitamin D (AA), Beckmann 
Access 25(OH) Vitamin D Total (BA), DiaSorin Liaison® 
25  OH vitamin D TOTAL (DL), IDS-iSYS 25-Hydroxy 
Vitamin DS (II), Roche Elecsys® Vitamin D Total (RE) and 
Siemens Advia Centaur Vitamin D Total (VitD) Assay (SA)] 
and one based on the LC-MS/MS technique are compared 
both in terms of their analytical and their clinical perfor-
mance. Our aim is to demonstrate the importance and the 
feasibility of the assessment of the clinical concordance 
of assay results for comparing the performance of various 
25OHD assays.
Materials and methods
Patient samples
Leftover blood samples taken from non-selected (e.g. by age, sex or 
vitamin D supplementation) adult in- and outpatients and previously 
analyzed in routine 25OHD assays were de-identified, divided into 
0.3- to 0.4-mL aliquots, and kept at –20 °C. Sample collection and 
processing and the handling of patient data were undertaken with 
adherence to effective legal and ethical regulations. In accordance, 
no samples or patient data were collected specifically for the pur-
poses of our investigations.
One hundred and sixty-two samples were involved in the study. 
Due to technical issues, only 114 results from the SA assay were even-
tually included. In a number of cases the automated tests delivered 
results lower than their low limit of quantification. These samples 
were excluded from the evaluation of the analytical performance.
The samples involved to assess the clinical concordance of 
results obtained using AA, BA, DL, II, RE and LC-MS/MS were from 
patients with a median age of 55 years, range, 4–91 years, male/
female ratio, 22.8:77.2. The median age of patients whose samples 
were included in the evaluation of the clinical performance of SA was 
54 years, range, 4–91 years, male/female ratio, 23.0:77.0.
Analysis using liquid chromatography-tandem mass 
spectrometry
LC-MS/MS assays were performed by Bionics Innovation Center Ltd. 
(Budapest, Hungary).
25-Hydroxyvitamin D2 (25OHD2) and 25OHD3 and the inter-
nal standard (IS) 26,26,26,27,27,27-D6-25-hydroxyvitamin D3 were 
purchased from Sigma-Aldrich Hungary Ltd. (Budapest, Hungary). 
LC-MS grade solvents were procured from VWR International Ltd. 
(Debrecen, Hungary). Ethyl acetate (LiChrosolv®) was obtained from 
Merck Hungary Ltd. (Budapest, Hungary). Nitrogen gas 5.0 was sup-
plied by Messer Hungarogáz Kft. (Budapest, Hungary).
The assays were conducted on a Perkin-Elmer Flexar FX 
ultra-performance liquid chromatograph coupled to an AB Sciex 
5500QTRAP mass spectrometer operated in the positive electrospray 
ionization mode. Nitrogen gas was supplied by a Peak Genius AB3G 
nitrogen generator (Per-Form Hungária Ltd, Budapest, Hungary).
Chromatographic separation was performed on a Phenomenex 
Kinetex XB-C18 column (50 × 2.1 mm, 1.7 µm) thermostatted at 35 °C. 
Water containing 0.1% formic acid (A) and methanol containing 0.3% 
formic acid (B) were used as mobile phase components. The gradient 
program started at 60% B, hold 1.0 min, then 100% B at 6.0 min, hold 
1.5 min, then 60% B at 8.0 min. The run time was 10 min, the eluent 
flow rate was 200 µL/min and 10 µL sample was injected.
The following parameter settings were applied for the opera-
tion of the mass spectrometer: source temperature, 500 °C; ioniza-
tion voltage, 5000 V; curtain gas, 40 psi; gas 1, 40 psi; gas 2, 40 psi; 
entrance potential, 10 V. Target analytes were detected by scheduled 
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multiple reaction monitoring at 7.45 min, with detection window of 
60 s and target scan time of 1.0000 s, applying the compound specific 
settings displayed in Table 1.
Sample preparation for LC-MS/MS
Calibrator solutions were prepared in a 1:1 mixture of water and 
methanol containing 25OHD2 (1.0, 2.0, 5.0, 10.0 or 20 ng/mL) and 
25OHD3 (1.0, 5.0, 20.0, 50.0 or 100 ng/mL). A 0.5-mL serum sample 
was diluted with 0.5 mL water after being spiked with 18 µL 1.4 µg/mL 
IS solution. The mixture was extracted twice with 1.0 mL ethyl ace-
tate. The organic phases were combined and evaporated to dryness 
under nitrogen. The residue was reconstituted with 300 µL water/
methanol 1:1 mixture and submitted for analysis.
Validation of LC-MS/MS
The LC-MS/MS method was validated prior to use. The limits of 
detection of 25OHD2 and 25OHD3 were 5 pg each. The low limits 
of quantitation in the serum matrix were 1.0 ng/mL each. Linearity 
was verified over the range of interest for both analytes. 25OHD2 and 
25OHD3 displayed a linear relationship of the concentration and the 
analyte/IS peak areas between 1–20 and 1–100 ng/mL, respectively 
(n = 3 for each level, weighting: 1/x2, r2 > 0.9900). The recoveries were 
64.7±9.2% and 62.4±7.7%, respectively. The intra-assay precision, 
determined at four levels, n = 5 for each level, was   ≤  9.2% and   ≤  7.4% 
for 25OHD2 and 25OHD3, respectively. The inter-assay precision, con-
ducted over five consecutive days, determined at four levels, n = 2 for 
each level, was   ≤  14.4% and   ≤  11.2%, respectively.
Automated assays
Samples were analyzed using the following reagent kits and plat-
forms: Abbott Architect 25-OH Total Vitamin D assay (ref. 3L52, lot: 
00614C000) on an Abbott Architect i2000 (Abbott Laboratories 
(Magyarország) Kft, Budapest, Hungary), Access 25(OH) Vitamin D 
Total assay (ref. B24838, lot: 335362) on a Beckmann Access analyzer 
(Beckman Coulter Magyarország Kft, Budapest, Hungary), DiaSorin 
Liaison® 25 OH vitamin D TOTAL assay (ref. 310600, lot: 130938) on a 
DiaSorin Liaison XL analyzer (Buda Labor Kft, Budapest, Hungary), 
IDS-iSYS 25-Hydroxy Vitamin DS assay (ref. IS-2700S, lot: 1861) on a 
IDS-iSYS Multi-Discipline Automated System (Diagon Kft, Budapest, 
Hungary), Roche Elecsys® Vitamin D Total assay (ref. 05894913190, 
lot: 175262) on a Roche Cobas 601 instrument (Roche Kft, Budapest, 
Hungary), and Siemens ADVIA Centaur Vitamin D (VitD) Total assay 
(ref. 10699201, lot: 10998063) on a Siemens Centaur XP platform 
(Diagon Kft, Budapest, Hungary). Analysis using SA was performed 
at the Central Laboratory, Petz Aladár Teaching Hospital, Győr, 
 Hungary. All other automated assays were conducted in the Depart-
ment of Laboratory Medicine, Semmelweis University (Budapest, 
Hungary).
Instruments, reagent kits, calibrators and controls were used in 
full compliance with the instructions of the manufacturers. Table 2 
presents the major features of the automated assays involved in the 
study.
Evaluation and statistical analysis
Quantitative analysis of the LC-MS/MS data was performed by apply-
ing a 1/x2 weight to the linear regression on the calibration points. 
25OHD2/IS and 25OHD3/IS peak area ratios were used for quantita-
tion. The results obtained on the automated platforms were quanti-
tated as proposed by the manufacturers of the assay kits.
Plots were generated in R [26] using the ‘beeswarm’ package and 
Microsoft Excel 2013. Passing-Bablok analysis was performed in R 
using the mcreg(method.reg = “PaBa”) function of the ‘mcr’ package. 
Concordance correlation coefficients (CCC) were determined using 
the epi.ccc() function of the ‘epiR’ package. The same function was 
used for generating data for the Bland-Altman analysis, with means 
and 95% confidence intervals calculated by basic functions of the R 
environment. The PA was determined by conducting the pairwise 
comparison of the clinical classifications of results (hypovitamino-
sis, lower than 20.0 ng/mL or euvitaminosis, not lower than 20.0 ng/
mL) and calculating the percentages of the agreeing classifications. 
The data sets were assumed to follow binomial distribution and 95% 
confidence intervals were calculated in R using the binom.test() func-
tion (Clopper-Pearson method).
Cohen’s κ values were calculated using GraphPad QuickCalcs 
(GraphPad Software Inc, La Jolla, CA, USA. Website: http://graphpad.
com/quickcalcs/kappa1/, accessed: 10 June 2016) and transformed 
into minimum percentage agreement (MPA) scores using a Monte-
Carlo simulation. Briefly, the value of cell ‘a’ was first generated as 
a random integer from 0 to n (162 or 114). The values of cells ‘b’ and 
‘c’ were random integers generated between 0 and n–a and n–(a+b), 
respectively. The value of cell ‘d’ was calculated as d = n–(a+b+c). In 
each simulation, 1,000,000 κ values were determined, and the PA 
was calculated as PA = a+d/n for each iteration with κi = κ. The mini-
mum PA was extracted from the resulting data set. The script of the 
Monte-Carlo simulation is available as Supplementary Material to 
this publication.
The statistical significance of the difference in clinical perfor-
mance was interrogated using McNemar’s hypothesis tests with a 95% 
confidence interval. For method pairs where the sum of the results in 
Table 1: Mass spectrometry settings for the analysis of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2.
Analyte   Ion type   Ion transition  Declustering potential  Collision energy  Cell exit potential
25-Hydroxyvitamin D3   Quantifier  401.3→257.3  120  20  20
25-Hydroxyvitamin D3   Qualifier   401.3→365.1  120  15  35
25-Hydroxyvitamin D2   Quantifier  413.3→395.2  125  12  30
D6-25-Hydroxyvitamin D3   Quantifier  407.3→389.3  125  13  20
D6-25-Hydroxyvitamin D3   Qualifier   407.3→371.3  125  17  30
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disagreement was lower than 25, McNemar’s exact  binomial test was 
applied using the mcnemar.exact() function of the ‘exact2x2’ package 
of R. For the rest of the method pairs, McNemar’s test with continuity 
correction was employed by running the mcnemar.test() function of 
the ‘stats’ package. The p-values were adjusted for multiple testing 
using Hommel’s formula.
All other calculations were performed using Microsoft Excel 
2013.
Results
The DL, AA, RE, BA, II, SA and LC-MS/MS assays deliv-
ered 25OHD concentrations with the following medians 
(with ranges in parentheses): 22.0 (5.3–49.6) ng/mL, 27.2 
(8.1–70.8) ng/mL, 24.5 (3.0–66.4) ng/mL, 25.3 (6.6–57.6) 
ng/mL, 33.1 (5.0–88.2) ng/mL, 24.4 (6.2–44.2) ng/mL, and 
32.1 (6.9–70.4) ng/mL, respectively. Only two samples were 
found to contain 25-hydroxyvitamin D2 (1.25 ng/mL and 
2.05 ng/mL) above the limit of quantitation using LC-MS/
MS, therefore, the comparison studies are effectively 
based on the 25-hydroxycholecalciferol levels. The raw 
assay results are shown in Figure 1.
The results of the comparisons of analytical perfor-
mance are shown in Table 3. The correlation coefficients 
of the Passing-Bablok analyses ranged between 0.604 (RE 
vs. SA) and 0.940 (AA vs. DL). The CCC was between 0.499 
(II vs. SA) and 0.876 (AA vs. RE).
The highest proportion of  < 20 ng/mL results was 
obtained with DL (39.5%), followed by the RE, AA, BA, 
SA, LC-MS/MS and II assays (34.0%, 29.6%, 29.0%, 28.1%, 
18.5% and 13.6%, respectively, Figure  2). The mean PA 
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Figure 1: Beeswarm plot of the 25-hydroxyvitamin D concentrations 
obtained using the various testing methods.
The red line corresponds to the 20 ng/mL level which is most 
frequently considered as the threshold for hypovitaminosis D. See 
the Materials and methods section for the full identification of the 
assays.
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ranged between 74.1% (DL vs. II, 95% confidence  interval: 
66.6%–80.6%) and 92.6% (II vs. LC-MS/MS, 87.4%–96.1%). 
The lowest mean κ value was obtained for DL vs. II (0.388), 
and the highest for AA vs. DL (0.757). The low 95% confi-
dence limits of these values correspond to minimum PA’s 
of 56.2% and 82.7%, respectively (Figure 3).
The 95% PA confidence intervals showed a close 
agreement with those obtained by transforming Cohen’s 
κ values into MPA, except for method pairs including II 
(Figure 3). Increasing the number of samples involved 
resulted in negligible changes in the PA values from a low, 
although method-dependent, sample size onwards. The 
diagrams which illustrate the consistency of PA scores 
from n = 100 are provided as Supplementary Material.
The symmetry of the disagreement in the clinical 
classification of results, along with their statistical sig-
nificance, is shown by Figure 4. The data indicate that in 
Figure 2: Bar chart of the proportions of 25-hydroxyvitamin D 
results lower (dark sections) or higher (light sections) than  
20 ng/mL obtained using the various testing methods.
See the Materials and methods section for the full identification of 
the assays.
Figure 3: Box plots displaying the percentage agreements (means and 95% confidence intervals, blue) and the minimum percentage agree-
ments obtained by transforming the calculated Cohen’s κ values statistics (means and 95% confidence intervals, green) using Monte-Carlo 
simulation.
See the Materials and methods section for the full identification of the assays.
many combinations either of the two methods was signifi-
cantly more likely to deliver positive results.
Discussion
Information on assay performance is highly valuable for 
clinical laboratories and clinicians, whether transferring 
to a new method or comparing test results coming from 
different laboratories for decision making. In contrast 
to method evaluation comprising part of the validation 
process or pre-marketing studies which require the dem-
onstration of assay properties against those of an estab-
lished reference method with an emphasis on analytical 
characteristics, comparison studies conducted in a clini-
cal context should focus on the clinical concordance of 
the assays. A typical setup is the evaluation of a candidate 
assay versus the method in use on a sample size that can 
be run within an acceptable framework of costs and time.
In this study, the experimental setup was intended to 
simulate method comparison in the clinical environment 
as described above. To this end, both the analytical and 
the clinical performance of the involved testing methods 
was compared on a medium-sized sample set. No refer-
ence method was used, instead, all of the pairwise combi-
nations of the involved assays were compared.
The Passing-Bablok regressions, Bland-Altman analy-
ses and the CCC values consistently demonstrated the lack 
of acceptable agreement in the analytical performance 
of the assays involved (Table 3). In the Passing-Bablok 
 analyses, 1 and 0 fell within the 95% confidence interval 
of the slope and the intercept, respectively, for only four 
method pairs (AA vs. BA, AA vs. SA, BA vs. SA and II vs. 
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LC-MS/MS). The confidence intervals were broad, and 
the correlation coefficients were by far beneath the limit 
of acceptability (r = 0.975 according to [27]). The Bland-
Altman analyses revealed small ( < 10%) biases in many 
comparisons, but the limits of agreement were unaccept-
ably wide in all cases. These findings are similar to those 
observed by others when these assays were compared to 
reference methods [28–30].
Despite the poor analytical agreement, the PA was 
high for all method pairs and within a narrow range 
(79.0%–89.5%) after excluding the two extreme values 
(Figure  3). These percentages indicate that the overall 
clinical concordance is predictable and, for several assay 
pairs, acceptable. A closer look also reveals, however, two- 
or even threefold differences in the proportions of positive 
results obtained using some of the methods (Figure  2). 
In addition, McNemar’s tests indicated a high degree of 
asymmetry in the disagreement through significant differ-
ences for 14 of the 21 method combinations, with “false 
positives” (results found to be lower than 20 ng/mL by one 
method of a pair) being obtained exclusively by one of the 
methods in six combinations.
Cohen’s κ is the only statistical tool employed in 
earlier publications to compare the clinical performance 
of the currently available 25OHD testing methods, never-
theless, its use has been criticized [31]. Figure 3 shows that 
PA and MPA values are in close agreement for the method 
pairs except those including II for which the MPA scores 
are substantially lower. The latter can be attributed to the 
small number of positive results and the consequently 
increased range of uncertainty obtained using the II assay. 
These results indicate that at medium sample size the PA 
can be used as a valid statistic to predict the degree of 
agreement, providing an alternative to Cohen’s κ statistic 
or the derived MPA. Because the variable underlying the 
PA follows a binomial distribution (agreement/disagree-
ment), the PA statistics are relatively insensitive to sample 
sizes except when smaller samples sets are used. In con-
trast, Cohen’s κ statistics and, especially, their standard 
deviations are very sensitive to the sample size [32, 33]. 
The chance of the biased interpretation of the PA, a well 
understood indicator, is predictably smaller than that of 
Cohen’s κ which, in the comparison of 25OHD assays, has 
been interpreted consistently using arbitrary thresholds 
and a vague judgement terminology (“good”, “fair”, etc). 
PA scores obtained in independent studies can also be 
compared efficiently which is a considerable challenge 
regarding the κ statistics due, again, to its dependence on 
the sample size and on the specific values in the contin-
gency tables.
The results of our study demonstrate that DL delivers 
significantly more 25OHD results lower than 20 ng/mL 
than the rest of the assays. Similarly, a significantly lower 
proportion of these results is obtained using LC-MS/MS 
and by far the lowest using II. On the other hand, all com-
binations of AA, BA, RE and SA are similar in their clinical 
Figure 4: Bar charts illustrating the asymmetry of method disagreement by displaying the proportions of samples assayed lower than 
20 ng/mL by only one of the methods within a method pair.
The asterisks indicate a significant disagreement in the clinical classifications of results (p < 0.05). See the Materials and methods section 
for the full identification of the assays.
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concordance including the proportions of  sub-cut-off 
25OHD concentrations, the PAs and, in line with these, 
the lack of significant differences in the delivery of posi-
tive results.
Three of the methods involved in the study underwent 
standardization in the VDSP RMP (Table 2). The results 
of the corresponding Deming regression studies were 
claimed as 1.01x–2.87, 0.94x+1.34 and 0.93x+2.89 for BA, II 
and SA with Pearson’s correlation coefficients of 0.95, 0.92 
and 0.99, respectively [34–36]. An interesting finding of 
the present investigation is that the clinical concordance 
of the results obtained using these assays did not reflect 
the impact of the standardization process. The Passing-
Bablok regression performed on the BA vs. SA results dem-
onstrated an outstanding agreement concerning the slope 
and the intercept, but, at the same time, a considerable 
random error component resulting in a correlation coef-
ficient of 0.733. This is in line with the negligible bias and 
the ±47.5% range in the limits of agreement obtained in 
the Bland-Altman analysis and with the degree of clinical 
concordance found (Table 3). The results are far worse for 
the BA vs. II and SA vs. II comparisons both in analytical 
and clinical respect, with all three error terms (constant, 
proportional and random) being sizeable, with a substan-
tial difference identified in the clinical classification of the 
assay outputs. These findings yield the conclusion that 
establishing the traceability of assays in the VDSP RMP 
does not provide sufficient evidence for the equivalence of 
the testing methods. While the standardization process is 
undoubtedly desirable for assay harmonization, the direct 
comparison of methods, both in analytical and clinical 
respect, seems inevitable in identifying the consequences 
of a method transfer or the comparison of results delivered 
by various assays for making clinical decisions.
Our study is not without limitations. First, patient 
samples were not selected and may include ones with 
matrix interferences with a selective impact on the results 
obtained using the various assays. Second, samples had 
been frozen for a prolonged period which, although 
25OHD levels were re-assayed after 12 months and showed 
no sign of degradation in the patient samples, might have 
given rise to interferences not typically encountered with 
freshly assayed specimens. Finally, the employed LC-MS/
MS method was validated but not standardized to the 
VDSP RMP, has not been tested in an external quality 
assessment scheme and does not resolve epimers from 
the 25OHD metabolites. Although none of the specimens 
had been taken from infants under 1 year of age, encoun-
tering substantial positive bias in some of the samples 
due to the presence of the 25OHD3 epimer could not be 
excluded.
Conclusions
The direct comparison of the analytical and clinical per-
formance of 25OHD assays remains important in the clini-
cal setting. The ratio of positive samples, the PA and the 
symmetry of disagreement as judged by hypothesis testing 
are together effective for comparing the clinical perfor-
mance of 25OHD assays. Transferring to a new method is 
likely to lead to a detectable change in the 25OHD levels 
observed in specific patients. The asymmetry of disagree-
ment should therefore be taken into consideration before 
changing the clinical classification of the vitamin D 
status. Finally, the interpretation of Cohen’s κ values can 
be improved if transformed into MPA.
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